The Ankrum Lab focuses on developing bioengineering strategies to overcome challenges in delivery and control of cell phenotype after transplantation. 

Cell-based therapies have the potential to restore function to a broad range of diseased and damaged tissues. However, this potential can only be realized if cells can be reliably delivered to the target tissue and remain functional. Using a combination of chemistry and biomaterials, we create tools that allow us to influence cell phenotype even after transplantation. These platform technologies have numerous applications to diabetes and its complications. We are currently developing a mesenchymal stem cell (MSC) based therapy to treat diabetic wounds through enhancing MSCs' angiogenic and anti-inflammatory properties. Other applications include enhancing beta cell therapy through promoting survival and long-term function of transplanted cells.

Recent News

Madeleine Humpal-Pash presenting her pitch at the undergraduate startup incubator

$5,000 awarded at end of semester pitches

Friday, December 9, 2022
Madeleine Humpal-Pash was among five University of Iowa students who shared $5,000 in prize money at the undergraduate Startup Incubator End of Semester Pitch Competition on Dec. 9 in the Bedell Entrepreneurship Learning Laboratory in Iowa City, Iowa.
Portrait of James Ankrum

UI professor to research collaborative regenerative medicine in Ireland

Thursday, April 14, 2022
James Ankrum, a University of Iowa biomedical engineering professor, will bring his expertise in cell biology to a world-renowned research lab in Dublin.
James Ankrum works with students in his lab

James Ankrum receives prestigious Fulbright award to study regenerative medicine in Ireland

Wednesday, March 23, 2022
James Ankrum, an associate professor in biomedical engineering, has been selected for a Fulbright Scholar Award in Ireland for the 2022-2023 academic year.